Iniciar sesión

Se requiere una suscripción a JoVE para ver este contenido. Inicie sesión o comience su prueba gratuita.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol streamlines retroviral vector production and murine T cell transduction, facilitating the efficient generation of mouse CAR-T cells.

Abstract

Engineered cell therapies utilizing chimeric antigen receptor (CAR)-T cells have achieved remarkable effectiveness in individuals with hematological malignancies and are presently undergoing development for the treatment of diverse solid tumors. So far, the preliminary evaluation of novel CAR-T cell products has predominantly taken place in xenograft tumor models using immunodeficient mice. This approach is chosen to facilitate the successful engraftment of human CAR-T cells in the experimental setting. However, syngeneic mouse models, in which tumors and CAR-T cells are derived from the same mouse strain, allow evaluation of new CAR technologies in the context of a functional immune system and comprehensive tumor microenvironment (TME). The protocol described here aims to streamline the process of mouse CAR-T cell generation by presenting standardized methods for retroviral transduction and ex vivo T cell culture. The methods described in this protocol can be applied to other CAR constructs beyond the ones used in this study to enable routine evaluation of new CAR technologies in immune-competent systems.

Introduction

Adoptive T cell therapies expressing chimeric antigen receptors (CARs) have revolutionized the field of cancer immunotherapy by harnessing the power of the adaptive immune system to specifically target and eliminate antigen-positive cancer cells1. While the success of CAR-T cell therapies targeting B cell malignancies has been clinically validated, preclinical studies performed in animal models remain vital for the development of new CARs targeting solid tumors. However, limited clinical efficacy has been demonstrated in solid tumor indications thus far, and it is becoming increasingly apparent that individual preclinical ....

Protocol

All animal procedures were performed with approval from the Institutional Animal Care and Use Committee (Columbia University, protocols AC-AABQ5551 and AC-AAAZ4470) using 6-8-week-old female BALB/c or CF57BL/6 mice weighing between 20-25 g. The animals were obtained from a commercial source (see Table of Materials). This protocol is structured around the 'days post-activation' of murine T cells, and viral production begins on Day -2. Retrovirus can be stored at -80 °C following initial produ.......

Representative Results

The protocol described here aims to standardize the process of murine T cell transduction for the generation of mouse CAR-T cells. Figure 1 provides a detailed description of the steps involved. The process begins with the production of retroviral vectors via co-transfection of viral components into Phoenix Eco cells. Figure 2 provides an image of the optimal density of Phoenix Eco cells on the day of transfection. Isolated T cells are then activated 24.......

Discussion

This protocol describes the steps and reagents necessary for the retroviral transduction of murine T cells to generate CAR-T cells for in vivo studies. Optimizing retroviral transduction conditions achieves robust CAR expression without the need for viral concentration through ultracentrifugation or additional reagents. However, there are multiple modifications that can be applied to this methodology.

While this protocol describes the example generation of a GFP-specific CAR, these me.......

Acknowledgements

We thank L. Brockmann for critical review of the manuscript. This work was supported by NIH 1R01EB030352 and UL1 TR001873.

....

Materials

NameCompanyCatalog NumberComments
0.45 μm filtersMilliporeSigmaSLHVR33RS
1 mL syringe Fisher Scientific 14-955-450
1.5 mL microcentrifuge tubes Fisher Scientific 05-408-135
10 mL syringe BD14-823-16E
100 μm strainerCorning07-201-432
15 cm TC treated cell culture dishesThermoFisher Scientific 130183
15 mL conical tubes Falcon14-959-70C
40 μm strainer Corning07-201-430
50 mL conical tubes Falcon14-959-49A
70 μm strainerCorning07-201-431
Attune NxT Flow Cytometer ThermoFisher Scientific 
BALB/C, 6-8 week old Jackson Laboratory651
B-Mercaptoethanol Gibco21985023
Bovine Serum Albumin GOLDBIOA-420-500
DMEM MediumGibco11965092
Dulbecco's Phosphate Buffered Saline (PBS), without Calcium and Magnesium Gibco14-190-250
DynaMag-2 Magnet Invitrogen12-321-D
EasySep Magnet Stemcell Technologies18000
EasySep Mouse T cell Isolation KitStemcell Technologies19851
FACS buffer BDBDB554657
Fetal bovine serum (FBS) CorningMT35011CV
GlutaMAXGibco35-050-061
G-Rex6Wilson Wolf80240M 
HEPES Buffer Solution Gibco15-630-080
Human recombinant IL-15 Miltenyi Biotec130-095-765
Human recombinant IL-2Miltenyi Biotec130-097-748
Human recombinant IL-7Miltenyi Biotec130-095-363
Lipofectamine 3000InvitrogenL3000008
MEM Non-Essential Amino Acids Solution Gibco11140-050
Mouse Anti-CD3 BV421Biolegend100228
Mouse Anti-CD3/CD28 DynabeadsGibco11-453-D
Mouse Anti-CD4 BV605BD563151
Mouse Anti-CD44 APC Biolegend103011
Mouse Anti-CD62L PE-Cy7TonboSKU 60-0621-U025
Mouse Anti-CD8 APC-Cy7TonboSKU 25-0081-U025
Nikon Ti2 with Prime 95B camera Nikon
Non-treated 24 well plates CytoOneCC7672-7524
Opti-MEMGibco31-985-062
pCL-EcoAddgene#12371
Penicillin/Streptomycin SolutionGibco15-070-063
Phoenix Eco cellsATCCCRL-3214
pMDG.2Addgene#12259
pMSCV_PGK_GFP28zN/AProduced by R.LV.
Purified sfGFPN/AProduced by R.LV.
RetroNectin ('transduction reagent')Takara BioT100B
RPMI 1640Gibco21875
Serological pipette 10 mLFisher Scientific 13-678-11E
Serological pipette 25 mLFisher Scientific 13-678-11
Serological pipette 5 mLFisher Scientific 13-678-11D
Sodium PyruvateGibco11-360-070
TC-treated 24 well plates Corning08-772-1
Trypan blue Gibco15-250-061

References

  1. June, C. H., Sadelain, M. Chimeric antigen receptor therapy. N Engl J Med. 379 (1), 64-73 (2018).
  2. Duncan, B. B., Dunbar, C. E., Ishii, K. Applying a clinical lens to animal models of car-t cell therapies. Mol Ther Meth....

Explore More Articles

Murine CAR T CellsChimeric Antigen Receptor T cellsSyngeneic Tumor ModelsRetroviral TransductionEx Vivo T Cell CultureSolid Tumor TreatmentImmune SystemTumor Microenvironment TMEEngineered Cell Therapies

This article has been published

Video Coming Soon

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados